Related Experiment Videos
Experience with antimicrobial combinations in urinary tract infections
1Department of Medicine, Ain Shams University, Cairo, Egypt.
Drugs Under Experimental and Clinical Research
|January 1, 1988
Summary
Four antimicrobial combinations effectively managed recurrent upper urinary tract infections with excellent microbiological success rates. These drug combinations were well-tolerated and offer benefits like broader spectrum activity and resistance prevention.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Recurrent upper urinary tract infections (UTIs) pose a significant clinical challenge.
- Antimicrobial resistance necessitates exploring effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and tolerability of four different antimicrobial combinations in managing recurrent upper UTIs.
- To assess the microbiological success rates of combination therapies.
Main Methods:
- A study involving 160 patients with recurrent upper UTIs.
- Four antimicrobial combinations were administered: rifampicin + trimethoprim, amoxycillin + clavulanic acid, ampicillin + sulbactam, and pivampicillin + pivmecillinam.
- Microbiological success rates were assessed initially and finally.
Main Results:
- All four antimicrobial combinations demonstrated excellent initial and final microbiological success rates.
- The drug combinations were consistently well-tolerated by patients.
- No significant adverse events were reported.
Conclusions:
- Antimicrobial combination therapy is a viable and effective option for recurrent upper UTIs.
- Combination therapy can broaden spectrum of activity, prevent resistance, and enhance antimicrobial effects.
- While monotherapy is standard, specific indications justify combination approaches in UTI management.